Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity

6 Jun 2019

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Chronic Lymphocytic Leukemia Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 31178407
DOI: 10.1016/j.chembiol.2019.05.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical ActivityPMID 31178407Read ↗

Polypharmacology is an enduring and nearly universal property of kinase inhibitorsSemantic proximity Read ↗

Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary TargetsSemantic proximity Read ↗

CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree?Semantic proximity Read ↗

The kinase polypharmacology landscape of clinical PARP inhibitorsSemantic proximity Read ↗

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017Semantic proximity Read ↗

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological ConditionsSemantic proximity Read ↗

DrugBank 5.0: a major update to the DrugBank database for 2018.Semantic proximity Read ↗

Spectrum and Degree of CDK Drug Interactions Predicts Clinical PerformanceSemantic proximity Read ↗

A Community Challenge for Pancancer Drug Mechanism of Action Inference from Perturbational Profile DataSemantic proximity Read ↗

A cancer pharmacogenomic screen powering crowd-sourced advancement of drug combination predictionSemantic proximity Read ↗

Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinomaSemantic proximity Read ↗

The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assaysSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.